Clinics in Dermatology
Volume 24, Issue 5 , Pages 430-437 , September 2006

Rheumatoid arthritis in dermatology

  • Tissa Hata, MD

      Affiliations

    • Division of Dermatology, Department of Medicine, University of California, San Diego School of Medicine, La Jolla, CA 92093-0943, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 858 657 7044; fax: +1 858 657 7045.
    • ,
  • Arthur Kavanaugh, MD

      Affiliations

    • Division of Rheumatology, Allergy and Immunology, Department of Medicine, Center for Innovative Therapy, University of California, San Diego School of Medicine, La Jolla, CA 92093-0943, USA

References 

  1. Kavanaugh AFLP. Clinical immunology. 2nd ed. London: Harcourt Publishers; 2001;
  2. Turesson C, McClelland RL, Christianson TJ, Matteson EL. No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: results from a community-based study. Arthritis Rheum. 2004;50:3729–3731
  3. Grassi W, De Angelis R, Lapadula G, Leardini G, Scarpa R. Clinical diagnosis found in patients with Raynaud's phenomenon: a multicentre study. Rheumatol Int. 1998;18:17–20
  4. Carroll GJ, Withers K, Bayliss CE. The prevalence of Raynaud's syndrome in rheumatoid arthritis. Ann Rheum Dis. 1981;40:567–570
  5. Saraux A, Allain J, Guedes C, Baron D, Youinou P, Le Goff P. Raynaud's phenomenon in rheumatoid arthritis. Br J Rheumatol. 1996;35:752–754
  6. Wigley FM, Flavahan NA. Raynaud's phenomenon. Rheum Dis Clin North Am. 1996;22:765–781
  7. Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis. 1996;55:122–127
  8. Blann AD, Illingworth K, Jayson MI. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol. 1993;20:1325–1330
  9. Flavahan NA, Flavahan S, Liu Q, et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000;43:1886–1890
  10. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford). 2005;44:145–150
  11. Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol. 2004;33:65–72
  12. Gordon DA, Stein JL, Broder I. The extra-articular features of rheumatoid arthritis. A systematic analysis of 127 cases. Am J Med. 1973;54:445–452
  13. Sienknecht CW, Urowitz MB, Pruzanski W, Stein HB. Felty's syndrome. Clinical and serological analysis of 34 cases. Ann Rheum Dis. 1977;36:500–507
  14. Schumacher HR, Gall EP. Rheumatoid arthritis: an illustrated guide to pathology, diagnosis, and management. Philadelphia: JB Lippincott Co; 1988;
  15. Kaye BR, Kaye RL, Bobrove A. Rheumatoid nodules. Review of the spectrum of associated conditions and proposal of a new classification, with a report of four seronegative cases. Am J Med. 1984;76:279–292
  16. Ahmed SS, Arnett FC, Smith CA, Ahn C, Reveille JD. The HLA-DRB1*0401 allele and the development of methotrexate-induced accelerated rheumatoid nodulosis: a follow-up study of 79 Caucasian patients with rheumatoid arthritis. Medicine (Baltimore). 2001;80:271–278
  17. Ziff M. The rheumatoid nodule. Arthritis Rheum. 1990;33:761–767
  18. Berhard G. Rheumatoid arthritis: etiology, diagnosis, management. Philadelphia: JB Lippincott Co; 1985;
  19. James W, Berger T, Elston D. Andrew's diseases of the skin: clinical dermatology. 10th edition. Philadelphia: WB Saunders; 2006;
  20. Hessian PA, Highton J, Kean A, Sun CK, Chin M. Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma. Arthritis Rheum. 2003;48:334–338
  21. Kato H, Yamakawa M, Ogino T. Complement mediated vascular endothelial injury in rheumatoid nodules: a histopathological and immunohistochemical study. J Rheumatol. 2000;27:1839–1847
  22. Ching DW, Petrie JP, Klemp P, Jones JG. Injection therapy of superficial rheumatoid nodules. Br J Rheumatol. 1992;31:775–777
  23. Breedveld FC, Valentijn RM, Westedt ML, Weening JJ. Rapidly progressive glomerulonephritis with glomerular crescent formation in rheumatoid arthritis. Clin Rheumatol. 1985;4:353–359
  24. Segal R, Caspi D, Tishler M, Fishel B, Yaron M. Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis. Arthritis Rheum. 1988;31:1182–1185
  25. Kaye O, Beckers CC, Paquet P, Arrese JE, Pierard GE, Malaise MG. The frequency of cutaneous vasculitis is not increased in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol. 1996;23:253–257
  26. Salvarani C, Macchioni P, Mantovani W, et al. Extraarticular manifestations of rheumatoid arthritis and HLA antigens in northern Italy. J Rheumatol. 1992;19:242–246
  27. Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol. 1994;21:33–36
  28. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol. 2002;29:62–67
  29. Voskuyl AE, Zwinderman AH, Westedt ML, Vandenbroucke JP, Breedveld FC, Hazes JM. Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. Ann Rheum Dis. 1996;55:190–192
  30. Vollertsen RS, Conn DL, Ballard DJ, Ilstrup DM, Kazmar RE, Silverfield JC. Rheumatoid vasculitis: survival and associated risk factors. Medicine (Baltimore). 1986;65:365–375
  31. Vollertsen RS, Conn DL. Vasculitis associated with rheumatoid arthritis. Rheum Dis Clin North Am. 1990;16:445–461
  32. Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76:377–384
  33. Geirsson AJ, Sturfelt G, Truedsson L. Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications. Ann Rheum Dis. 1987;46:727–733
  34. Sayah A, English JC. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol. 2005;53:191–209[quiz 210-2]
  35. Golding JR, Hamilton MG, Gill RS. Arteritis of rheumatoid arthritis. Br J Dermatol. 1965;77:207–210
  36. Bywaters EG, Scott JT. The natural history of vascular lesions in rheumatoid arthritis. J Chronic Dis. 1963;16:905–914
  37. Watts RA, Carruthers DM, Scott DG. Isolated nail fold vasculitis in rheumatoid arthritis. Ann Rheum Dis. 1995;54:927–929
  38. Voskuyl AE, Hazes JM, Zwinderman AH, et al. Diagnostic strategy for the assessment of rheumatoid vasculitis. Ann Rheum Dis. 2003;62:407–413
  39. Sigal LH. The neurologic presentation of vasculitic and rheumatologic syndromes. A review. Medicine (Baltimore). 1987;66:157–180
  40. Matsuo T, Koyama T, Morimoto N, Umezu H, Matsuo N. Retinal vasculitis as a complication of rheumatoid arthritis. Ophthalmologica. 1990;201:196–200
  41. Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore). 1981;60:288–297
  42. Babian M, Nasef S, Soloway G. Gastrointestinal infarction as a manifestation of rheumatoid vasculitis. Am J Gastroenterol. 1998;93:119–120
  43. Mizuno K, Ikeda K, Saida Y, Takenaka R, Shibata M, Takeuchi T. Hepatic hemorrhage in malignant rheumatoid arthritis. Am J Gastroenterol. 1996;91:2624–2625
  44. Heurkens AH, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med. 1991;151:2249–2254
  45. Upchurch KS, Heller K, Bress NM. Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis. J Am Acad Dermatol. 1987;17(2 Pt 2):355–359
  46. Unger L, Kayser M, Nusslein HG. Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis. 2003;62:587–588
  47. Hirche D, Rubbert A, Lunau L, Krieg T, Eming SA. Successful treatment of refractory rheumatoid arthritis–associated leg ulcerations with adalimumab. Br J Dermatol. 2005;152:1062–1064
  48. Knab J, Goos M, Dissemond J. Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy. J Eur Acad Dermatol Venereol. 2005;19:243–246
  49. Still G. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47
  50. Elkon KB, Hughes GR, Bywaters EG, et al. Adult-onset Still's disease. Twenty-year follow-up and further studies of patients with active disease. Arthritis Rheum. 1982;25:647–654
  51. Magadur-Joly G, Billaud E, Barrier JH, et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis. 1995;54:587–590
  52. Kadar J, Petrovicz E. Adult-onset Still's disease. Best Pract Res Clin Rheumatol. 2004;18:663–676
  53. Larson EB. Adult Still's disease. Evolution of a clinical syndrome and diagnosis, treatment, and follow-up of 17 patients. Medicine (Baltimore). 1984;63:82–91
  54. Mahmud T, Hughes GR. Intravenous immunoglobulin in the treatment of refractory adult Still's disease. J Rheumatol. 1999;26:2067–2068
  55. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005;52:1794–1803
  56. von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137:1000–1005
  57. Lyon CC, Smith AJ, Beck MH, Wong GA, Griffiths CE. Parastomal pyoderma gangrenosum: clinical features and management. J Am Acad Dermatol. 2000;42:992–1002
  58. McCalmont CS, Leshin B, White WL, Greiss FC, Jorizzo JL. Vulvar pyoderma gangrenosum. Int J Gynaecol Obstet. 1991;35:175–178
  59. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395–409[quiz 410-2]
  60. Callen JP. Neutrophilic dermatoses. Dermatol Clin. 2002;20:409–419
  61. Adachi Y, Kindzelskii AL, Cookingham G, et al. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol. 1998;111:259–268
  62. Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol. 1992;31:574–577
  63. Gardner LW, Acker DW. Triamcinolone and pyoderma gangrenosum. Arch Dermatol. 1972;106:599–600
  64. Braun-Falco M, Stock K, Ring J, Hein R. Topical platelet-derived growth factor accelerates healing of myelodysplastic syndrome–associated pyoderma gangrenosum. Br J Dermatol. 2002;147:829–831
  65. de Cock KM, Thorne MG. The treatment of pyoderma gangrenosum with sodium cromoglycate. Br J Dermatol. 1980;102:231–233
  66. Tsele E, Yu RC, Chu AC. Pyoderma gangrenosum—response to topical nitrogen mustard. Clin Exp Dermatol. 1992;17:437–440
  67. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3:149–158
  68. Wollina U, Karamfilov T. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol Venereol. 2000;14:187–190
  69. Slevin M, Kumar S, Gaffney J. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J Biol Chem. 2002;277:41046–41059
  70. Farris DR, Schutzer PJ, Don PC, Silverberg NB, Weinberg JM. Resolution of pyoderma gangrenosum after therapy with lyophilized bovine collagen matrix. Dermatology. 2003;206:284–285
  71. Jolles S, Niclasse S, Benson E. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol. 1999;140:564–565
  72. Patrone P, Bragadin G, De Francesco V, Frattasio A, Stinco G. Pyoderma gangrenosum of the scalp treated with cyclosporine A. Int J Dermatol. 2002;41:916–918
  73. Coors EA, von den Driesch P. Pyoderma gangrenosum in a patient with autoimmune haemolytic anaemia and complement deficiency. Br J Dermatol. 2000;143:154–156
  74. Kaminska R, Ikaheimo R, Hollmen A. Plasmapheresis and cyclophosphamide as successful treatments for pyoderma gangrenosum. Clin Exp Dermatol. 1999;24:81–85
  75. Burruss JB, Farmer ER, Callen JP. Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol. 1996;35(5 Pt 1):720–724
  76. Fukuhara K, Urano Y, Kimura S, Hori K, Arase S. Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone. Br J Dermatol. 1998;139:556–558
  77. Kark EC, Davis BR, Pomeranz JR. Pyoderma gangrenosum treated with clofazimine. Report of three cases. J Am Acad Dermatol. 1981;4:152–159
  78. Hecker MS, Lebwohl MG. Recalcitrant pyoderma gangrenosum: treatment with thalidomide. J Am Acad Dermatol. 1998;38:490–491
  79. Reynolds NJ, Peachey RD. Response of atypical bullous pyoderma gangrenosum to oral minocycline hydrochloride and topical steroids. Acta Derm Venereol. 1990;70:538–539
  80. Lyon CC, Kirby B, Griffiths CE. Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. Br J Dermatol. 1999;140:562–564
  81. Nousari HC, Lynch W, Anhalt GJ, Petri M. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol. 1998;134:1509–1511
  82. Kaur MR, Lewis HM. Severe recalcitrant pyoderma gangrenosum treated with infliximab. Br J Dermatol. 2005;153:689–691
  83. Ackerman A. Histopathologic diagnosis of inflammatory skin diseases: a method by pattern analysis. Philadelphia: Lea and Febiger; 1978;
  84. MacAya A, Servitje O, Jucgla A, Peyri J. Rheumatoid neutrophilic dermatitis associated with pyoderma gangrenosum. Br J Dermatol. 2000;142:1246–1248
  85. Lowe L, Kornfeld B, Clayman J, Golitz LE. Rheumatoid neutrophilic dermatitis. J Cutan Pathol. 1992;19:48–53
  86. Mashek HA, Pham CT, Helm TN, Klaus M. Rheumatoid neutrophilic dermatitis. Arch Dermatol. 1997;133:757–760
  87. Scherbenske JM, Benson PM, Lupton GP, Samlaska CP. Rheumatoid neutrophilic dermatitis. Arch Dermatol. 1989;125:1105–1108
  88. Yamamoto T, Ohkubo H, Nishioka K. Rheumatoid neutrophilic dermatitis. Int J Dermatol. 1994;33:798–800
  89. Hirota TK, Keough GC, David-Bajar K, McCollough ML. Rheumatoid neutrophilic dermatitis. Cutis. 1997;60:203–205
  90. Harkaway K, Elenitas R, Margolis DJ. Erythematous papules in a patient with rheumatoid arthritis. Rheumatoid neutrophilic dermatitis (RND). Arch Dermatol 1995;131:1196, 1199-200.
  91. Sanchez JL, Cruz A. Rheumatoid neutrophilic dermatitis. J Am Acad Dermatol. 1990;22(5 Pt 2):922–925
  92. Kavanaugh A, Cohen S, Cush JJ. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis. J Rheumatol. 2004;31:1881–1884
  93. Lee SJ, Kavanaugh A. Adverse reactions to biologic agents: focus on autoimmune disease therapies. J Allergy Clin Immunol. 2005;116:900–905
  94. Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am. 2004;30:237–255
  95. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol. 2001;137:893–899
  96. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002;97:1408–1414
  97. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549
  98. Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol. 2004;31:1912–1917
  99. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315–1324
  100. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19–31
  101. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31:1955–1958
  102. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol. 2000;27:2041–2044
  103. Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti-tumor necrosis factor-alpha therapy–induced vasculitis: case series. J Rheumatol. 2003;30:2287–2291
  104. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti–TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford). 2002;41:1126–1132
  105. Guillevin L, Mouthon L. Tumor necrosis factor-alpha blockade and the risk of vasculitis. J Rheumatol. 2004;31:1885–1887
  106. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–2293
  107. Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am. 2003;29:185–202
  108. Fratazzi C, Arbeit RD, Carini C, Remold HG. Programmed cell death of Mycobacterium avium serovar 4–infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages. J Immunol. 1997;158:4320–4327
  109. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha–neutralizing agent. N Engl J Med. 2001;345:1098–1104
  110. Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti–tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. 2004;63:1538–1543
  111. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti–tumor necrosis factor alpha therapy. Arthritis Rheum. 2003;48:3013–3022
  112. Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ. Salmonella septicemia in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum. 2003;48:1853–1857
  113. Chan AT, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J. 2002;78:47–48
  114. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001;76:653–656
  115. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha–blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666–R676
  116. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513–2518
  117. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother. 2004;38:54–57
  118. Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol. 2004;3:439–440
  119. Beuthien W, Mellinghoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum. 2004;50:1690–1692
  120. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis. 2005;64(Suppl 2):ii87–ii90[discussion ii91-2]
  121. Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol. 2003;15:380–386

PII: S0738-081X(06)00100-3

doi: 10.1016/j.clindermatol.2006.07.008

Clinics in Dermatology
Volume 24, Issue 5 , Pages 430-437 , September 2006

Article Tools